Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis

被引:56
作者
Qi, Jing
Liu, Ning
Zhou, Yuan
Tan, Yaohong
Cheng, Yanhong
Yang, Chunzheng
Zhu, Zhenping [1 ]
Xiong, Dongsheng
机构
[1] Peking Union Med Coll, Inst Hematol, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Chinese Acad Sci, Changchun Inst Appl Chem, Lab New Drug Res & Mass Spectrometry, Changchun 130022, Peoples R China
[4] Jilin Univ, Inst Life Sci, Changchun 130023, Peoples R China
基金
中国国家自然科学基金;
关键词
multidrug resistance; sorcin; Bcl2/Bax; apoptosis; proteomics; 2D gel analysis;
D O I
10.1016/j.bbrc.2006.08.042
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In an attempt to identify novel proteins involved in the emergence of multidrug resistance (MDR) in leukemia cells, we adopted a proteomics approach to analyze protein expression patterns in leukemia cell lines, K562, and its MDR counterpart, K562/A02. Combining high resolution two-dimensional gel electrophoresis and mass spectrometry, we compared the protein expression profiles between K562 and K562/A02. A total number of 22 protein spots with altered abundances of more than 2-fold were detected and 14 proteins were successfully identified. Consistent with our previous observations by cDNA microarray, sorcin, a 22-kDa calcium-binding protein, was also identified by this proteomic approach with a 10.4-fold up-regulation in K562/A02 cells. Overexpression of sorcin protein in K562 cells by gene transfection led to significantly reduced cytosolic calcium level and increased resistance to cell apoptosis. Further, leukemia cell lines over-expressing sorcin also showed up-regulation of Bcl-2, along with decreased level of Bax. Taken together, our results suggest that sorcin plays an important role in the emergence of MDR in leukemia cells via regulating cell apoptosis pathways, thus may represent both a new MDR marker for prognosis and a good target for anti-MDR drugs development. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 25 条
  • [1] P-glycoprotein: from genomics to mechanism
    Ambudkar, SV
    Kimchi-Sarfaty, C
    Sauna, ZE
    Gottesman, MM
    [J]. ONCOGENE, 2003, 22 (47) : 7468 - 7485
  • [2] Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
    Baer, MR
    George, SL
    Dodge, RK
    O'Loughlin, KL
    Minderman, H
    Caligiuri, MA
    Anastasi, J
    Powell, BL
    Kolitz, JE
    Schiffer, CA
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 2002, 100 (04) : 1224 - 1232
  • [3] The versatility and universality of calcium signalling
    Berridge, MJ
    Lipp, P
    Bootman, MD
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2000, 1 (01) : 11 - 21
  • [4] Mammalian ABC transporters in health and disease
    Borst, P
    Elferink, RO
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2002, 71 : 537 - 592
  • [5] Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B
    Boyd, RS
    Adam, PJ
    Patel, S
    Loader, JA
    Berry, J
    Redpath, NT
    Poyser, HR
    Fletcher, GC
    Burgess, NA
    Stamps, AC
    Hudson, L
    Smith, P
    Griffiths, M
    Willis, TG
    Karran, EL
    Oscier, DG
    Catovsky, D
    Terrett, JA
    Dyer, MJS
    [J]. LEUKEMIA, 2003, 17 (08) : 1605 - 1612
  • [6] Drug resistance factors in acute myeloid leukemia:: a comparative analysis
    Filipits, M
    Stranzl, T
    Pohl, G
    Heinzl, H
    Jäger, U
    Geissler, K
    Fonatsch, C
    Haas, OA
    Lechner, K
    Pirker, R
    [J]. LEUKEMIA, 2000, 14 (01) : 68 - 76
  • [7] Multidrug resistance in cancer: Role of ATP-dependent transporters
    Gottesman, MM
    Fojo, T
    Bates, SE
    [J]. NATURE REVIEWS CANCER, 2002, 2 (01) : 48 - 58
  • [8] Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
    Greenberg, PL
    Lee, SJ
    Advani, R
    Tallman, MS
    Sikic, BI
    Letendre, L
    Dugan, K
    Lum, B
    Chin, DL
    Dewald, G
    Paietta, E
    Bennett, JM
    Rowe, JM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1078 - 1086
  • [9] Identification of novel targets for cancer therapy using expression proteomics
    Hanash, SM
    Madoz-Gurpide, J
    Misek, DE
    [J]. LEUKEMIA, 2002, 16 (04) : 478 - 485
  • [10] Hirose Masao, 2003, Journal of Medical Investigation, V50, P126